Biogen's Litifilimab Shows Positive Long-Term Results in Cutaneous Lupus Trial
Long-term data from Biogen’s (BIIB) phase 2 trial of litifilimab, a treatment for cutaneous lupus erythematosus, demonstrated that patients achieved clear skin and reduced disease activity after one year. The results come from the phase 2 portion of the AMETHYST Phase 2/3 study. The findings suggest potential efficacy in managing this chronic autoimmune condition affecting the skin. These data may support further development or regulatory discussions for litifilimab as a treatment option, potentially expanding Biogen’s portfolio in immunology.
Tickers: $BIIB
Topics: Biogen clinical trial data cutaneous lupus erythematosus litifilimab